New combo therapy aims to wipe out CLL cells in untreated patients

NCT ID NCT05336812

Recruiting now Disease control Sponsor: Ohio State University Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests two different drug combinations in people with untreated chronic lymphocytic leukemia (CLL). Participants first take acalabrutinib alone, then are randomly assigned to add either obinutuzumab or venetoclax. The goal is to see which combination better clears cancer cells from the bone marrow, potentially leading to longer remission. The study enrolls 52 adults who have not had prior CLL treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib, obinutuzumab, venetoclax
What this could lead to: If successful, this could lead to a more effective initial treatment for CLL that helps patients achieve deep, long-lasting remission without needing immediate further therapy.
What could go wrong: This is an early phase 2 trial with only 52 participants, so results may not apply to all CLL patients. The combinations may cause side effects like infections or bleeding, and it's not yet known if they work better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.